InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

RECURSION PHARMACEUTICALS, INC.

RXRX Clue Score60
United States Fiscal year ends December CIK 0001601830 Results filed 2 Nov 2026
Add to watchlist

What the insiders did Scheduled selling only

Individual transactions

14
Insider
Date
Role
Action
Shares
Price
Amount
Robert Hershberg
6 Oct 2026
Director
Sold after exercise
25,000
$5.00
$125.00K
Christopher Gibson
5 Jun 2026
Director
Sold after exercise
40,000
$3.62
$144.80K
Christopher Gibson
22 May 2026
Director
Sold after exercise
40,000
$3.08
$123.20K
Christopher Gibson
7 May 2026
Director
Sold after exercise
40,000
$3.37
$134.80K
Christopher Gibson
22 Apr 2026
Director
Sold after exercise
40,000
$3.61
$144.40K
Christopher Gibson
7 Apr 2026
Director
Sold after exercise
40,000
$3.10
$124.00K
Christopher Gibson
23 Mar 2026
Director
Sold after exercise
40,000
$3.25
$130.00K
Christopher Gibson
19 Feb 2026
Director
Sold after exercise
40,000
$3.46
$138.40K
Christopher Gibson
4 Feb 2026
Director
Sold after exercise
40,000
$4.12
$164.80K
Christopher Gibson
20 Jan 2026
Director
Sold after exercise
40,000
$4.47
$178.80K
Christopher Gibson
5 Jan 2026
Director
Sold after exercise
40,000
$4.25
$170.00K
Christopher Gibson
19 Dec 2025
Chief Executive Officer
Sold after exercise
40,000
$4.50
$180.00K
Christopher Gibson
4 Dec 2025
Chief Executive Officer
Sold after exercise
40,000
$4.63
$185.20K
Christopher Gibson
19 Nov 2025
Chief Executive Officer
Sold after exercise
40,000
$4.16
$166.40K
Show all 35 transactions →

What was left out

Form 4 filings counted 72
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 21
Sales straight out of an exercise 14
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 4,766,042
History held since 19 Apr 2021